AstraZeneca Exanta Liver Safety Is Key Approval Issue, Company Says

AstraZeneca's discussions with FDA over the safety profile of its investigational anticoagulant Exanta will center on elevated liver enzyme levels reported during clinical trials

More from Archive

More from Pink Sheet